Maria A. Pabon

1 week ago | healio.com | Erik Swain |Richard Smith |Maria A. Pabon

Key takeaways: Finerenone reduced risk for new-onset atrial fibrillation vs. placebo in a pooled analysis. The patient population included those with certain kinds of heart failure and those with diabetic kidney disease. CHICAGO — Finerenone prevented new-onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes or heart failure with mildly reduced or preserved ejection fraction, according to new data from FINE-HEART.

Sep 19, 2024 | onlinelibrary.wiley.com | Maria A. Pabon |Muthiah Vaduganathan |Brian Claggett |Safia Chatur

Introduction Heart failure (HF) hospitalizations often signal poor prognosis and are associated with significant healthcare expenses.1 Patients with HF with improved ejection fraction (HFimpEF) have a lower risk of HF hospitalizations as compared to patients with HF with reduced ejection fraction (HFrEF),2 but remain at risk for adverse clinical outcomes.3-7 We have previously shown that about 30% of participants in DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with...

May 27, 2024 | onlinelibrary.wiley.com | Maria A. Pabon |Muthiah Vaduganathan |Carolyn S.P. Lam

Corresponding Author Maria A. Pabon Cardiovascular Medicine Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA Corresponding author. Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA. Tel: +1 857 307-1960, Fax: +1 857 307-1944, Email: [email protected] for more papers by this author

Feb 3, 2024 | jacc.org | Alberto Foà |Muthiah Vaduganathan |Brian Claggett |Maria A. Pabon

ABSTRACTBackgroundHypotension is a potential adverse effect of sacubitril/valsartan, but there are limited data regarding the predictors and implications of treatment-related hypotension in HFmrEF and HFpEF. ObjectivesWe investigated predictors of treatment-associated hypotension, clinical outcomes after hypotension, and the relationship between LVEF and incidence of hypotension in the PARAGON-HF trial.